EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response

Ramón Gimeno iD, Clara Ribas-Llauradó iD, David Pesque iD, Evelyn Andrades, Bruno Cenni, Barbara Ambros, Ramon Pujol iD, Ana M Giménez-Arnau iD

Clinical and Translational Allergy · 2023-03 · 13 (3)

DOI: 10.1002/clt2.12227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 04.03.2023. Verfasst von Ramón Gimeno und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunology, Department of Pathology, Hospital del Mar, Barcelona, Spain. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite advances in the treatment of chronic urticaria, in a significant percentage of the patients symptoms are not fully controlled with conventional approaches. New strategies under development include blocking intracellular mediators of mast cell and basophil activation.

Objective

We aim to investigate the effects of the Bruton's tyrosine kinase (BTK) inhibitor remibrutinib on human blood basophils and CD34 + ‐derived mast cells activation induced by serum obtained from chronic urticaria patients.

Methods

Twenty‐two patients with chronic spontaneous urticaria (mean age 52 years, 27% women) and 22 patients with chronic inducible urticaria (46 years, 27% women) were included in the study together with a sex‐matched control group. Patients were classified as responders or non‐responders to anti‐IgE therapy on the basis of their clinical data, FcεR1a expression on blood basophils and total IgE levels. Changes on CD63 expression—as an activation marker‐, were used to evaluate in vitro the response of basophils and mast cells to serum exposure and the inhibitory effects of remibrutinib.

Results

Remibrutinib inhibits degranulation induced by IgE cross‐linking in mast cells and basophils and also the activation triggered by factors present in the sera of spontaneous and inducible chronic urticaria patients. Patient's serum induces a greater degranulation of effector cells than controls. Activation of mast cells and basophils by patient sera and remibrutinib effects were not related to omalizumab responsiveness.

Conclusion

Remibrutinib inhibits activation of human basophils and mast cells induced in vitro by exposure to the serum of chronic urticaria patients independently of their response to omalizumab.

Schlagwörter

Stichwörter der Autor:innen

Bruton's tyrosine kinaseIgEbasophilschronic urticariamast cellsomalizumabremibrutinib

Autor:innen und Institutionen

  • Laboratory of Immunology, Department of Pathology, Hospital del Mar, Barcelona, Spain.
  • Department Immnology, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
  • Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.
  • Department of Dermatology, Hospital del Mar, IMIM, Universitat Pompeu Fabra, Barcelona, Spain.
  • Department of Research, BC Novartis Institutes for BioMedical Research, Novartis, Basel, Switzerland.
  • Department of Clinical Development, BA Global Drug Development, Novartis, Basel, Switzerland.

ORCID-Profile: Ramón Gimeno, Clara Ribas-Llauradó, David Pesque, Ramon Pujol, Ana M Giménez-Arnau

Förderung

  • Instituto de Salud Carlos III
  • Novartis

Zitieren

APA

Gimeno, R., Ribas-Llauradó, C., Pesque, D., Andrades, E., Cenni, B., Ambros, B., Pujol, R., & Giménez-Arnau, A. M. (2023). Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response. Clinical and Translational Allergy, 13(3). https://doi.org/10.1002/clt2.12227

Vancouver

Gimeno R, Ribas-Llauradó C, Pesque D, Andrades E, Cenni B, Ambros B, et al. Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response. Clinical and Translational Allergy. 2023;13(3). doi:10.1002/clt2.12227

BibTeX
@article{Gimeno2023,
  author = {Gimeno, Ramón and Ribas-Llauradó, Clara and Pesque, David and Andrades, Evelyn and Cenni, Bruno and Ambros, Barbara and Pujol, Ramon and Giménez-Arnau, Ana M},
  title = {Remibrutinib inhibits hives effector cells stimulated by serum from chronic urticaria patients independently of FcεR1 expression level and omalizumab clinical response},
  journal = {Clinical and Translational Allergy},
  year = {2023},
  volume = {13},
  number = {3},
  doi = {10.1002/clt2.12227}
}
Kostenlos starten →